Egenesis has 6 close competitors: BioLinq, Calyxo, Kriya Therapeutics.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
EgenesisBioLinqCalyxoZocdocAbridgeGene-edited pig kidney xenotransplantation biotech company
Egenesis competes with 6 companies here: BioLinq, Calyxo, Kriya Therapeutics, Redcliffe Lifetech, Zocdoc, Abridge.
Egenesis was last valued at $350M (post-money, Feb 2021). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The closest biotechnology / healthcare peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Egenesis is a private company; its shares do not trade on a public exchange.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
